C-Type Natriuretic Peptide (CNP) (1-22), human TFA|cas:1966153-17-2|西域试剂

C-Type Natriuretic Peptide (CNP) (1-22), human TFA,99.78%

产品编号：Bellancom-P1237A| CAS NO：1966153-17-2| 分子式：C₉₅H₁₅₈F₃N₂₇O₃₀S₃| 分子量：2311.62

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1237A	￥1400.00	杭州北京（现货）
Bellancom-P1237A	￥2200.00	杭州北京（现货）
Bellancom-P1237A	￥8800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

C-Type Natriuretic Peptide (CNP) (1-22), human TFA

产品介绍

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)，是 CNP 的 1-22 片段，是一种利钠肽受体 B (NPR-B) 激动剂。C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) 抑制由生理激动剂组胺和 5-HT 刺激或直接由 Forskolin 刺激的 cAMP 合成。CNP 是一种有效的、内皮衍生的松弛剂和生长抑制因子。

生物活性

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.

体外研究

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human:

Dose (nM/kg)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	CL_tot (mL/min/kg)	Vd_ss (mL/kg)
20	320±54	1.02±0.18	1.42±0.45	63.9±11.9	64.2±5.1

PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human:

Dose (nM/kg)	Cmax (pM/mL)	Tmax (min)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	BA (%)
50	9.02±3.74	5.0±0.0	152±73	13.9±3.4	10.0±5.0	19±9

Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL_tot=total clearance, T_1/2=half-life period, BA=bioavailability.
i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human:

Dose (nM/kg)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	CL_tot (mL/min/kg)	Vd_ss (mL/kg)
20	320±54	1.02±0.18	1.42±0.45	63.9±11.9	64.2±5.1

PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human:

Dose (nM/kg)	Cmax (pM/mL)	Tmax (min)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	BA (%)
50	9.02±3.74	5.0±0.0	152±73	13.9±3.4	10.0±5.0	19±9

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

H₂O : 2 mg/mL (0.87 mM; Need ultrasonic)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. [Content Brief]

. Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. [Content Brief]

. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

在线咨询

服务热线

13911702513
18601927057

微信客服